Match!
Philippe Merle
French Institute of Health and Medical Research
PathologyHepatocellular carcinomaSorafenibCancer researchMedicine
213Publications
32H-index
4,961Citations
What is this?
Publications 207
Newest
#1Stephen L. Chan (CUHK: The Chinese University of Hong Kong)H-Index: 42
#2Andrew X. Zhu (Harvard University)H-Index: 68
Last. Mohamed BouattourH-Index: 14
view all 18 authors...
Source
#1Philippe MerleH-Index: 32
#2Do Hoon Lim (SMC: Samsung Medical Center)H-Index: 42
Last. Masayuki KurosakiH-Index: 36
view all 16 authors...
Source
#1Richard S. Finn (UCLA: University of California, Los Angeles)H-Index: 55
#2Shukui QinH-Index: 31
Last. Philippe MerleH-Index: 32
view all 19 authors...
4596Background: In the Phase III IMbrave150 trial, statistically significant and clinically meaningful improvements in OS and PFS were seen with atezo + bev vs sor in pts with unresectable HCC who ...
Source
#1Arndt Vogel (MHH: Hannover Medical School)H-Index: 39
#2Lorenza Rimassa (Humanitas University)H-Index: 28
Last. Michael Leibfried (Genentech)
view all 13 authors...
4585Background: The IMbrave150 pivotal study in unresectable HCC showed superiority of atezolizumab + bevacizumab (atezo + bev) vs sorafenib for OS and PFS. Based on these data supporting first-lin...
Source
#1Richard S. FinnH-Index: 55
#2Shukui QinH-Index: 31
Last. Ahmed Omar KasebH-Index: 28
view all 21 authors...
Abstract Background The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinom...
12 CitationsSource
#1MasatoshiKudo (Kindai University)H-Index: 78
#2Peter R. GalleH-Index: 91
Last. Bruno DanieleH-Index: 32
view all 22 authors...
BACKGROUND & AIMS: Limited data on treatment of elderly patients with hepatocellular carcinoma (HCC) increase the unmet need. REACH and REACH-2 were global phase III studies of ramucirumab in patients with HCC after prior sorafenib, where patients with alpha-fetoprotein (AFP) >/=400 ng/mL showed an overall survival (OS) benefit for ramucirumab. These post-hoc analyses examined efficacy and safety of ramucirumab in patients with HCC and baseline AFP >/=400 ng/mL by three prespecified age subgroup...
Source
#1Lorenza RimassaH-Index: 28
#2Tiziana PressianiH-Index: 13
Last. Philippe MerleH-Index: 32
view all 3 authors...
2 CitationsSource
#1Marc Bonnin (University of Lyon)H-Index: 6
#2Nadim Fares (University of Lyon)H-Index: 1
Last. Serge Lebecque (University of Lyon)H-Index: 54
view all 23 authors...
Source
#1Do Hoon Lim (SMC: Samsung Medical Center)H-Index: 42
#2Philippe MerleH-Index: 32
Last. MasatoshiKudo (Kindai University)H-Index: 78
view all 11 authors...
542Background: Regorafenib significantly improved overall survival (OS) versus placebo in patients (pts) with uHCC who progressed on prior sorafenib therapy in the phase 3 RESORCE trial. The multic...
Source
#1Julien EdelineH-Index: 23
#2Thomas YauH-Index: 32
Last. Fiona Taylor (Adelphi University)H-Index: 11
view all 20 authors...
483Background: SOR is approved as 1L therapy for pts with aHCC, but there is still an unmet need to help improve or maintain HRQoL. This phase 3 study compared HRQoL of NIVO vs SOR as 1L therapy in...
3 CitationsSource
12345678910